Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant
- 97 Downloads
The study examined in simulations the interaction between a muscle relaxant and an antagonist that binds the free molecules of the relaxant, as experimentally demonstrated for rocuronium and sugammadex. The hypothetical muscle relaxant D and the hypothetical antagonist X were assigned pharmacokinetic properties to define the time course of their concentrations in plasma, and pharmacodynamic properties to define binding of D to either X or the receptors at the motor end plates. D, X, and their complex DX were postulated to diffuse between plasma and the effect compartment. The first and the fourth twitch elicited in sequential trains of four stimuli were evaluated in a model of neuromuscular transmission. The rates of reactions were formulated as differential equations and the equations solved numerically. If the affinity of D for X is comparable to that of D for the postsynaptic receptors, doses of X two to four times larger than the dose of D produce a fast and a complete recovery of the twitches. Smaller doses of X or lower affinities of D for X accomplish a slower and only partial recovery. Additionally, the complete restoration of twitch strength within 2 min after the injection of X requires that X and DX diffuse into the effect compartment. The simulations reveal the physicochemical, pharmacokinetic, and pharmacodynamic properties of an antagonist that restores twitch strength by sequestering the free molecules of the muscle relaxant.
KeywordsNondepolarizing neuromuscular blocking drugs Reversal agents Sequestration Sugammadex Simulation of neuromuscular block Simulation of the reversal
Unable to display preview. Download preview PDF.
- 1.Adam JM, Bennett DJ, Bom A, Clark JK, Feilden H, Hutchinson EJ, Palin R, Prosser A, Rees DC, Rosair GM, Stevenson D, Tarver GJ and Zhang MQ (2002). Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 45: 1806–1816 CrossRefPubMedGoogle Scholar
- 2.Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC and Zhang M-Q (2002). A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem (Int Ed Engl) 41: 266–270 Google Scholar
- 6.Epemolu O, Bom A, Hope F, Mason R (2003) Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 99:632–637; discussion 636AGoogle Scholar
- 7.Hope F and Bom A (2001). Org 25969 reverses rocuronium-induced neuromuscular blockade in the cat without important haemodynamic effect. Eur J Anaesthesiol 18(Suppl 23): 99 Google Scholar
- 8.Mason R and Bom A (2001). Org 25969 causes selective reversal of neuromuscular block induced by steroidal NMBs in anaesthetized giunea pigs. Eur J Anaesthesiol 18(Suppl 23): 100 Google Scholar
- 10.Booij L, Bom A, van Egmont J and van de Pol F (2001). Neuromuscular blockade induced by steroidal NMBs can be rapidly reversed by Org 25969 in the anaesthetized monkey. Eur J Anaesthesiol 18(Suppl 23): 100 Google Scholar
- 21.Bom A, Bradley M, Cameron K, Clark JK, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang MQ and van Egmond J (2002). A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 41: 266–270 CrossRefPubMedGoogle Scholar
- 22.Nigrovic V, Bhatt SB, Amann A (2006) First human exposure to Org 25969. Anesthesiology 105:427; author reply 427Google Scholar